RAL-trap Intermediary for Retinal A2E Accumulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for dry form age-related macular degeneration (AMD) and Stargardt disease are inadequate, as they fail to effectively arrest disease progression and preserve vision, primarily due to the accumulation of cytotoxic A2E in retinal tissue.
Innovation Solution
Administering a therapeutic compound, known as a RAL-trap, which competes with phosphatidyl ethanolamine to limit the formation of A2E by forming a Schiff base adduct with trans-RAL, thereby reducing A2E accumulation in retinal tissue.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for dry form AMD and Stargardt disease, then disease progression continues, but vision loss is not effectively prevented
Solution Approach 1:
The patent introduces a therapeutic compound as an intermediary substance that specifically binds to trans-RAL, preventing it from reacting with phosphatidylethanolamine to form A2E. This intermediary compound acts as a mediator between trans-RAL and the harmful A2E formation pathway, effectively blocking the toxic reaction without directly removing existing A2E or altering the underlying disease process.
Solution Approach 2:
The patent extracts or removes trans-RAL from the harmful reaction pathway by having the therapeutic compound bind to it, forming a stable adduct that prevents trans-RAL from converting to A2E. This effectively takes the harmful trans-RAL out of the disease-causing process before it can generate toxic A2E in the retinal tissue.
2Object-affected harmful factors
If trans-RAL reacts with phosphatidylethanolamine to form A2E, then A2E accumulates in retinal tissue causing toxicity, but the natural visual cycle process is disrupted
Solution Approach 1:
The therapeutic compound serves as an intermediary that selectively intercepts trans-RAL before it can react with phosphatidylethanolamine. This mediator approach allows the system to prevent A2E formation without fundamentally altering the visual cycle components, maintaining the stability of the natural retinal metabolic pathways while blocking the harmful side reaction.
Solution Approach 2:
The patent converts the harmful reaction between trans-RAL and phosphatidylethanolamine into a beneficial outcome by introducing a therapeutic compound that binds trans-RAL. This transforms the potentially harmful trans-RAL accumulation into a controlled therapeutic interaction, where the bound trans-RAL is safely removed from the toxic pathway without disrupting the essential visual cycle functions.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The RAL-trap effectively prevents the formation of A2E, thereby halting the progression of dry AMD and Stargardt disease, preserving vision by reducing the toxic effects of A2E on retinal pigment epithelium cells.
Implementation Method 1
a therapeutic compound, known as a RAL-trap, which competes with phosphatidyl ethanolamine to limit the formation of A2E by forming a Schiff base adduct with trans-RAL
Data Source
AI summary
Compositions and methods for treating macular degeneration and other forms of retinal disease whose etiology involves the accumulation of A2E and/or lipofuscin, and, more specifically, for preventing the formation and/or accumulation of A2E are disclosed.